About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, February 11th, 2015

The QualityStocks
Daily Stock List


CTD Holdings, Inc. (CTDH)

Wall Street Resources reported earlier on CTD Holdings, Inc. (CTDH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CTD Holdings, Inc. is a family of biotechnology growth companies that distributes and manufactures cyclodextrin-based products. CTD’s individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes. These are for biotechnology and life science companies engaged in research, pharmaceutical, medical device, cosmetics and nutrition markets.

OTCQB-listed CTD Holdings has its head office in Alachua, Florida. The Company has been operating since 1989. CTD Holdings became a fully reporting public company in May 1994. Experienced chemistry and manufacturing veterans lead the Company.

Sphingo Biotechnology, Inc. is a division of CTD. Sphingo Biotechnology is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and often fatal genetic disease in young children.

NanoSonic Products, Inc. is also a division of CTD Holdings. NanoSonic operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. In addition, CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers worldwide from the world's largest catalog of cyclodextrins.

The aforementioned companies offer a broad array of cyclodextrin related manufacturing services to global customers. These manufacturing services include custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes.

In January, CTD Holdings announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Type II Drug Master File No. 28889 covering its second-generation Trappsol® Cyclo™ orphan drug product. The file permits clinicians and researchers to cite the drug in Investigational New Drug applications (INDs) and request FDA approval for compassionate use treatment of Niemann-Pick Type C.

First-generation Trappsol® Cyclo™ is in powder form. Second-generation Trappsol® Cyclo™ is a proprietary, ready-to-use sterile liquid solution. It improves safety, enables precise dosing, and allows treatment without the services of a compounding pharmacist. CTD Holdings’ Sphingo Biotechnology division will provide the drug to physicians and researchers whose INDs have received FDA approval. The product is being used under like regulatory regimens in Europe and South America to treat Niemann-Pick Type C.

CTD Holdings, Inc. (CTDH), closed Wednesday's trading session at $0.70, up 0.16%, on 17,100 volume with 8 trades. The average volume for the last 60 days is 12,790 and the stock's 52-week low/high is $0.09/$1.05.

Viking Investments Group, Inc. (VKIN)

Greenbackers, SmallCapFinancialWire, and UndiscoveredEquities reported on Viking Investments Group, Inc. (VKIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Viking Investments Group’s intention is to acquire, invest in, and/or provide professional advisory and consulting services to companies undergoing or anticipating periods of fast growth, major change or ownership transition. The Company targets under-valued investments with realistic appreciation potential and a defined exit strategy. Viking Investments Group has its corporate headquarters in New York, New York. The Company’s shares trade on the OTC Market Group’s OTCQB.

Viking Investments Group’s main emphasis is in evaluating and completing investments in North America, primarily in the Oil & Gas and Real Estate sectors, with suitable diversification and balance between each division. Viking is not an investment company, as defined by the Investment Company Act of 1940.

Last week, Viking Investments Group announced that it executed an agreement with Cytron Capital Group, Inc. regarding a gravel and timber operation in the Province of Saskatchewan. Viking has agreed to purchase 50 percent of the issued and outstanding shares of Cytron Gravel Corp., a wholly-owned subsidiary of Cytron, subject to certain conditions being satisfied. This includes Cytron Gravel having the exclusive right to remove and sell all of the sand, gravel and other surface and undersurface materials, and all of the saleable timber, from or in respect of a targeted parcel of property in Naicam, Saskatchewan. Cytron Gravel expects to secure the rights on or before March 17, 2015.

Today, Viking Investments Group announced that on February 10, 2015, it signed a non-binding Letter of Intent (LOI) with AUR Overseas Holdings Limited (BVI) (AUR), where Viking expressed interest in loaning AUR up to USD$350M to facilitate the development by AUR of a luxury, 5-star resort on the island of Dhapparu, Maldives (the Chedi Resort). It is to be managed by an internationally-recognized, premier hotel management company, GHM Hotels. The resort will cater to a niche segment of high-end luxury travellers/guests in Maldives and global investors.

Viking Investments Group, Inc. (VKIN), closed Wednesday's trading session at $0.30, even for the day, on 52,575 volume with 4 trades. The average volume for the last 60 days is 39,284 and the stock's 52-week low/high is $0.0326/$0.60.

InVivo Therapeutics Holdings Corp. (NVIV)

OurHotStockPicks, SmallCapVoice, TopPennyStockMovers, Xtremepicks, and TheMicrocapNews reported on InVivo Therapeutics Holdings Corp. (NVIV), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

InVivo Therapeutics Holdings Corp. is a biomaterials and biotechnology company concentrating on the development and commercialization of novel drug delivery technologies and biopolymer devices for the treatment of spinal cord injuries (SCI) and other nervous system conditions. The Company earned the David S. Apple Award in 2011 from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. InVivo Therapeutics Holdings is headquartered in Cambridge, Massachusetts.

InVivo Therapeutics formed in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital.  The Company’s goal is to create a new paradigm of care by taking a novel approach to SCI.

InVivo Therapeutics focuses on neuroprotection instead of focusing only on regeneration. The intention of its products are to protect the spinal cord after primary injury through mitigating the bleeding, inflammation, and further cell death that result from the body’s immune response to SCI.

The Company has pioneered a new treatment platform using a biocompatible polymer-based device intended to promote structural support for spinal cord regeneration. This is while improving functional recovery and prognosis after a traumatic SCI.  In preclinical studies, the Neuro-Spinal Scaffold promoted cell adhesion, neurite sprouting, the growth of remodeled spinal cord tissue containing myelinated axons, and improved motor function.

This first clinical study (U.S. Food and Drug Administration (FDA) approved) is a pilot trial to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to start commercialization under a Humanitarian Device Exemption (HDE).

Recently, InVivo Therapeutics announced that a second subject was enrolled in the pilot study of the Company’s Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, North Carolina. The aim of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold and to gather preliminary evidence of effectiveness.

This month, InVivo Therapeutics announced the appointment of Mr. Mark D. Perrin as Chairman of InVivo’s Board of Directors, effective immediately.  Mr. Perrin has served as a Board member and Chief Executive Officer of the Company since January 2014. In addition, the Company announced this week the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015.

InVivo Therapeutics Holdings Corp. (NVIV), closed Wednesday's trading session at $2.16, down 2.26%, on 1,058,611 volume with 555 trades. The average volume for the last 60 days is 785,398 and the stock's 52-week low/high is $0.4651/$2.67.

Rand Worldwide, Inc. (RWWI)

FeedBlitz reported previously on Rand Worldwide, Inc. (RWWI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rand Worldwide, Inc. is a foremost provider of technology solutions and professional services to innovative engineering and design companies around the world. The Company provides complete solutions that empower companies to take better advantage of technology, improve workflow processes, as well as enhance the skills of their people. This in turn, promotes increased competitiveness, productivity, and profitability. Rand Worldwide has close to 50 locations throughout North America. Rand has its headquarters in Framingham, Massachusetts. The Company’s shares trade on the OTC Markets’ OTCQB.

Rand Worldwide’s international divisions consist of ASCENT- Center for Technical Knowledge; IMAGINiT Technologies; and Rand 3D. The ASCENT- Center for Technical Knowledge division is the leading developer of professional training materials and knowledge products for engineering software applications.

IMAGINiT Technologies delivers comprehensive services to assist companies in harnessing the total potential of their design technology. IMAGINiT Technologies services include technology solutions, professional services, and training & support.

Rand 3D focuses on providing professional, high-quality training solutions for Dassault Systèmes and PTC software users. Rand 3D is a recognized Dassault Systèmes Solutions Partner, providing software solutions for CATIA, DELMIA, ENOVIA, 3DVIA and PLM Express.

Rand Worldwide’s IMAGINiT Technologies division earlier released an updated version of its Scan to BIM software, Scan to BIM 2015.1. This latest release features automated piping tools specifically designed to save mechanical, electrical and plumbing (MEP) engineers and scanning professionals time when identifying, placing and connecting pipes from a point cloud to a model created with Autodesk Revit software.

Earlier this month, Rand Worldwide announced that its IMAGINiT Technologies and Rand Facilities Management divisions are now united under the IMAGINiT Technologies brand. The first service created from this new collaboration, the FM and BIM Connection Service, enables AEC firms to demonstrate the value of extending the rich data within the building information model (BIM) into the facilities management phase of the building lifecycle. IMAGINiT’s FM and BIM Connection Service removes the barriers between BIM and facilities management through sharing the BIM data in an integrated workplace management system, ARCHIBUS.

Rand Worldwide, Inc. (RWWI), closed Wednesday's trading session at $2.22, up 0.45%, on 5,223 volume with 12 trades. The average volume for the last 60 days is 19,902 and the stock's 52-week low/high is $0.96/$2.24.

Pressure BioSciences, Inc. (PBIO)

SmallCapFinancialWire reported this week on Pressure BioSciences, Inc. (PBIO), SmallCapVoice, MarketWireStocks, Center Stage Stocks, StockRockandRoll, and PennyStockLocks.com did earlier, and today we report on the Company, here at the QualityStocks Daily Newsletter.

Pressure BioSciences, Inc. focuses on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (PCT).  PCT is a patented, enabling technology platform with multiple applications in the life sciences sample preparation market. PCT utilizes cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. To date, the Company has installed more than 250 PCT systems in approximately 160 sites globally.  Pressure BioSciences is headquartered in South Easton, Massachusetts.

The Company is centering its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications. Its main application development and sales efforts are in the biomarker discovery and forensics areas.

The PCT Sample Preparation System (PCT SPS) allows for the safe, fast, and reproducible extraction of DNA, RNA, small molecules, and proteins from a broad variety of cells and tissues, especially those considered ‘hard-to-lyse’. The PCT SPS employs a Barocycler NEP3220, in tandem with PULSE™ Tubes.

Pressure BioSciences’ products include Barocycler Instruments, Shredders, PULSE Tubes (PT), PCT MicroTubes and PCT MicroCaps, PCT µPestle System, The Barozyme™ HT48, as well as Kits & Reagents. Additionally, the Company is an authorized distributor of Constant Systems Ltd. products in the U.S., Mexico, and Canada.

Yesterday, Pressure BioSciences announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System.  In addition, the Company announced the receipt of a request for a quotation for the possible purchase of a second Barozyme HT48 System. This request came from an existing European customer. The Barozyme HT48 is a first-in-class, high throughput, PCT-based instrument. It can process up to 48 samples simultaneously using the Company's proprietary BaroFlex 8-well, single-use processing strips. Collectively, the new Barozyme HT48 instrument and BaroFlex 8-well processing strips make up the Barozyme HT48 High-throughput System (the Barozyme HT48 System).

Pressure BioSciences announced in September 2014 plans to build and ship nine Barozyme HT48 High-throughput Systems for independent evaluation.  In November and December 2014, it announced the installation of the first three evaluation systems.

Mr. Richard T. Schumacher, Pressure BioSciences’ President and Chief Executive Officer, said, "We plan to install three more evaluation systems in the coming weeks: one at an academic research facility in MA, one at a cancer research company in CA, and one in a well-known, non-profit research center in Sweden. We expect the three new sites, like the existing three sites, to generate, publish, and present data that we expect to provide strong support to our Barozyme HT48 sales efforts."

Pressure BioSciences, Inc. (PBIO), closed Wednesday's trading session at $0.255, up 2.04%, on 363,142 volume with 60 trades. The average volume for the last 60 days is 44,678 and the stock's 52-week low/high is $0.132/$0.775.

Cirque Energy, Inc. (EWRL)

PennyStocks24, Information Solutions Group, and USA Market News reported previously on Cirque Energy, Inc. (EWRL), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Cirque Energy, Inc. concentrates on the generation and delivery of clean energy and energy efficient solutions. This includes Combined Heat and Power (CHP) projects, industrial cogeneration, waste-to-energy, biomass, natural gas, and building energy efficiency improvements. The Company has developed a strategic plan to create sustainable, renewable energy with waste-to-energy power plants and the production of waste derived fuels. An energy services company (ESCO), Cirque Energy is based in Detroit, Michigan and the Company’s shares trade on the OTCQB.

Cirque Energy provides the above-mentioned services to a varied client base. This includes industrial and commercial customers; municipalities, universities, schools, and hospitals (MUSH); and federal, state and local clients. Cirque operates with long-term supply agreements to process waste materials into valuable recyclables and reduce waste volume going into landfills by up to 85 percent.

The Company, as an ESCO, usually provides its services so that the new infrastructure is developed and owned by Cirque Energy. Project energy is subsequently sold to a customer using different structures that require little or no capital outlay by the customer.

The Company is working in partnership with Northrop Grumman Corp. to bring to market a deployable gasification unit (DGU), which can use solid waste to supplement traditional fuels used to generate CHP. Cirque Energy has proprietary gasification technology designed for CHP applications that can use waste fuels to produce low cost, renewable energy in the 200-2,500 kW market.

The DGUs use Cirque Energy's gasification and syngas condition technology, combined with conventional reciprocating engine generator technology.  Any carbon-based waste stream of around 2-10 tons daily can be cleanly and efficiently turned into CHP energy. CHP is an efficient and clean approach to producing electric power and useful thermal energy from a single fuel source.

Cirque Energy will evaluate a facility’s potential for implementation of a CHP project, for little or no upfront costs. The review can additionally include an evaluation of existing facility energy use to ascertain if energy efficiency measures can be put into operation to help offset overall energy requirements.

Today, Cirque Energy announced that it filed its quarterly report on Form 10-Q for the quarter ended September 30, 2014 with the U.S. Securities and Exchange Commission (SEC) and that it is now current with its filings.

Cirque Energy, Inc. (EWRL), closed Wednesday's trading session at $0.0185, up 8.82%, on 334,709 volume with 19 trades. The average volume for the last 60 days is 402,161 and the stock's 52-week low/high is $0.0099/$0.0299.

Amerityre Corp. (AMTY)

Real Pennies, CoolPennyStocks, and Stock Rich reported previously on Amerityre Corp. (AMTY), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Amerityre Corp. engages in the research and development (R&D), manufacture, and sale of polyurethane tires. It has invented new polyurethane foam and elastomer materials that the Company believes are superior to rubber in a number of tire applications. Its advanced polyurethane materials are environmentally friendly and can be recycled. Amerityre is based in Boulder City, Nevada.

The Company has developed a high density, closed cell foam material - using proprietary polyurethane chemical formulations – which it believes is superior in low speed foam tire applications. Amerityre’s materials are UV and ozone resistant and long-lasting. Its foam tires can never go flat; therefore, Amerityre calls them Flatfree™. The Company’s tires consist of high density foam and they exhibit low rolling resistance. The polyurethane foam tires do not absorb water and suffer performance degradation in wet environments.
The foundation of Amerityre’s polyurethane material technology is on two proprietary formulations. One is closed-cell polyurethane foam. This is a lightweight material with high load-bearing capabilities for low duty cycle applications. The other is Elastothane™, a high performance polyurethane elastomer with high load-bearing capabilities for high duty applications.

Amerityre is focusing on three segments of the tire market. These are closed-cell polyurethane foam tires, polyurethane elastomer forklift tires, and agricultural tires. Concerning agricultural tires, Amerityre has developed two products for this market, one used in irrigation and one used in planting. Both products have successfully field tested.

Regarding closed-cell polyurethane foam tires, the Company currently manufactures several lines of closed-cell polyurethane foam tires for bicycles, hand trucks, lawn and garden, wheelbarrow, and medical mobility products. Pertaining to polyurethane elastomer forklift tires, Amerityre has developed solid polyurethane forklift tires made of Elastothane™. The Company produces and sells more than 20 sizes for Class 1, 4 and 5 forklifts.

Concerning industrial tires, Amerityre manufactures solid elastomer tires made of its Elastothane™ and Kryon™ formulations. This technology can replace rubber with superior performing polyurethane for forklift and skid steer tires.

The sale of polyurethane foam tires to original equipment manufacturers (OEMs), distributors and dealers accounts for most of Amerityre’s current revenue. The Company can produce a wide range of products for the low duty cycle tire market. During 2014, it introduced a new low cost formulation positioned to compete within the commodity segment of this market. Its marketing efforts continue to build customer relationships with OEMs and further develop distribution networks to expand business and product sales.

Amerityre Corp. (AMTY), closed Wednesday's trading session at $0.05, up 4.17%, on 1,500 volume with 1 trade. The average volume for the last 60 days is 19,900 and the stock's 52-week low/high is $0.0201/$0.104.


The QualityStocks
Company Corner


Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.1018, off by 7.20%, on 48,700 volume with 9 trades. The stock’s average daily volume over the past 60 days is 95,300, and its 52-week low/high is $0.058/$0.24.

Sibling Group Holdings, Inc. announced today that its subsidiary Urban Planet Mobile™ ("UPM") will be implementing its web-based writing practice tool, Writing Planet™, through a partnership with Integrative Counseling Services Limited to work with Lok Sin Tong Schools in Hong Kong, China. Through this initial purchase, Lok Sin Tong, a non-profit organization in Hong Kong that runs 14 primary and secondary schools, with total enrollments of more than 9,000, will use the technology of Writing Planet for several schools including Lok Sin Tong Young Ko Hsiao Lin Secondary School, Lok Sin Tong Yu Kan Hing Secondary School, and Lok Sin Tong Leung Chik Wai Memorial School, among others.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling Group's Urban Planet Mobile Announces Partnership for Writing Planet in Hong Kong Secondary Schools

Sibling Group's Urban Planet Mobile(TM) Enters Indian Market, Announces New Mobile Distribution

Sibling Group Completes Urban Planet Mobile(TM) Acquisition, Appoints New CEO to Lead International Expansion

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.0949, up 26.53%, on 12,330 volume with 3 trades. The stock’s average daily volume over the past 60 days is 36,599, and its 52-week low/high is $0.032/$0.31.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding (MITD) Launches New Website with Investor Relations Suite

MIT Holding, Inc. Names Tommy J. Duncan as President

MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services

Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.44, up 3.53%, on 186,296 volume with 48 trades. The stock’s average daily volume over the past 60 days is 111,379, and its 52-week low/high is $0.3401/$1.10.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA (OTCQX: ZERO) Announces Engagement of QualityStocks Investor Relations Services

STWA Appoints Energy Industry Executive Thomas A. Bundros to Board of Directors

STWA Issues Letter to Shareholders

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.18, up 5.26%, on 19,500 volume with 10 trades. The stock’s average daily volume over the past 60 days is 53,013, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.04, up 5.82%, on 39,647 volume with 13 trades. The stock’s average daily volume over the past 60 days is 106,368, and its 52-week low/high is $0.03/$0.855.

Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power - Letter from President to Shareholders

Well Power Inc. to host second webinar on proprietory micro-refinery technology

Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.063, up 1.61%, on 179,081 volume with 24 trades. The stock’s average daily volume over the past 60 days is 676,434, and its 52-week low/high is $0.0555/$0.255.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial

International Stem Cell Corporation to Conduct Parkinson's Disease Clinical Study in Australia

International Stem Cell Corporation to Present at Biotech Showcase(TM) 2015

Pan Global Corp. (PGLO)

The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.0073, up 1.39%, on 3,727 volume with 4 trades. The stock’s average daily volume over the past 60 days is 82,003, and its 52-week low/high is $0.005/$0.248.

Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.

The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.

Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.

Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer

Pan Global Corp. Company Blog

Pan Global Corp. News:

Pan Global, Corp. Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017

Pan Global, Corp. Shareholder Update: Small-Hydro Plant Connected to Power Grid in Northern India

Pan Global, Corp. Increases Equity Stake in 5.7 MW Small-Hydro Plant in Northern India


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251